Triptorelina

Chemical data

Formula

C64H82N18O13

Molecular weight

1311.4 g/mol

IUPAC name

(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide

SMILES

CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)[C@@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@@H]8CCC(=O)N8

InChIKey

VXKHXGOKWPXYNA-PGBVPBMZSA-N

XLogP

-0.3

Polar surface area

490 Ų

H-bond donors

17

H-bond acceptors

15

Formal charge

0

via PubChem

Drug data · ChEMBL

Max clinical phase

Approved

Molecule type

Protein

First approval

2000

Admin. routes

parenteral

Indications

neoplasm, infertility, endometriosis, breast carcinoma

via ChEMBL · EBI

• Triptorelin for the treatment of endometriosis.Expert opinion on pharmacotherapy · 2014
• Triptorelin embonate (6-month formulation).Drugs · 2010
• Triptorelin depot for the treatment of children 2 years and older with central precocious puberty.Expert review of clinical pharmacology · 2018
• Triptorelin in the management of prostate cancer.Future oncology (London, England) · 2013
• Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer.Drugs · 2017

via PubMed

Wikidata facts

Mass

1310.630875

Has use

medication

via Wikidata · CC0